Achieve Life Sciences (ACHV) Short-Term Debt issuances (2022)
Achieve Life Sciences (ACHV) posted Short-Term Debt issuances of -$169000.0 for Q4 2022, down 112.0% on a QoQ basis from $1.4 million in Q2 2022.
Achieve Life Sciences (ACHV) Short-Term Debt issuances (2022) Analysis & Trends
Achieve Life Sciences' Short-Term Debt issuances history runs 1 years deep, the most recent figure standing at -$169000.0 for Q4 2022.
- Quarterly Short-Term Debt issuances changed N/A year-over-year to -$169000.0 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $1.3 million (changed N/A YoY) and the FY2022 annual result came in at $1.3 million, changed N/A from the prior year.
- Short-Term Debt issuances was -$169000.0 for Q4 2022 at Achieve Life Sciences, down from $1.4 million in the prior quarter.
- Across five years, Short-Term Debt issuances topped out at $1.4 million in Q2 2022 and bottomed at -$169000.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -33,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 58.20 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Achieve Life Sciences | 326.16 Mn | 326.16 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -169,000.00 |
| Dec 31, 2022 | -169,000.00 |
| Jun 30, 2022 | 1.41 Mn |
| Jun 30, 2022 | 1.41 Mn |
| Mar 31, 2022 | 91,000.00 |
| Mar 31, 2022 | 91,000.00 |